Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Task-adaptive multimodal molecular representations for structure-sensitive property prediction

Structure-sensitive properties (SSPs), including activity cliffs and chirality-dependent properties, challenge molecular machine learning because small structural perturbations can cause abrupt property changes and invalidate smooth structure–property assumptions. Here, we present CAMF (Chirality- and Activity-cliff-aware Multimodal Framework), a task-adaptive framework that models SSPs through selective integration of complementary molecular evidence. To systematically evaluate this problem, we construct SSPBench, a benchmark spanning 77 conventional ADMET and physicochemical tasks together with activity-cliff and chirality-sensitive benchmarks. CAMF integrates molecular embeddings and expert-defined descriptors using random-forest-based feature selection and adaptive fusion, enabling property-specific prioritization of informative signals while reducing multimodal redundancy. Across ten baselines, CAMF achieves the best overall performance on SSP tasks, improving mean R2 by up to 29.5% on activity-cliff datasets and reducing MAE by up to 23.3% on 90 364 chiral molecules with TD-DFT-computed optical rotatory strengths. Ablation analyses show that these gains arise from task-adaptive multimodal integration rather than naive feature concatenation. More broadly, our results reveal that modality relevance is strongly task-dependent, with descriptors and 3D geometry becoming especially important in non-smooth property regimes. Case studies further support the interpretability and practical utility of CAMF in identifying activity-associated substructures and clinically relevant toxicity liabilities.

Shaolong Lin, Si-Long Zhai, Shi-Hang Wang et al. · 0 citations
Open access Jul 2026

Structure-Based Design of New Nonpeptidic Covalent Mpro Inhibitors against SARS-CoV-2 and Omicron Variants

The main protease (Mpro) is a prime target for anti-SARS-CoV-2 drugs. Herein, we describe the structure-based covalent modifications that generate new nonpeptidic covalent Mpro inhibitors. The compounds exhibit strong inhibition against Mpro at submicromolar levels. The deuterated lead compound exhibits submicromolar antiviral activity against wild-type SARS-CoV-2 and Omicron variants. Biolayer interferometry analysis indicates a strong binding affinity for Mpro. The mass spectrometry results confirm the covalent bonding of the compound with the cysteine residue of Mpro. Taken together, the data may support the deuterated compound as a new lead for developing anti-SARS-CoV-2 drugs and further reveal the feasibility of using chloroacetyl for structure-based covalent drug design.

Honglei Bao, Ling-Chen Sun, Shilin Gong et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.